Şerifhan Mirac Sarı
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Şerifhan Mirac Sarı has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Abdullah Burak Uygur
Alanya Alaaddin Keykubat Üniversitesi Tıp Fakültesi
2 shared publications - Ahmet Al
Department of Psychiatry, Faculty of Medicine Alanya Alaaddin Keykubat University Antalya Türkiye
2 shared publications - Ali Emre Öz
Department of Psychiatry, Faculty of Medicine Alanya Alaaddin Keykubat University Antalya Türkiye
2 shared publications - Kadir Karakuş
Department of Psychiatry, Faculty of Medicine Alanya Alaaddin Keykubat University Antalya Türkiye
2 shared publications - Rabia Önem
Department of Psychiatry Alaşehir State Hospital Manisa Türkiye
2 shared publications - Selime Çelik Erden
Department of Psychiatry, Faculty of Medicine Alanya Alaaddin Keykubat University Antalya Türkiye
2 shared publications
Latest Publications
- 25 October 2026
- Published by Wiley in International Journal of Eating Disorders
Disordered Eating Behaviors and Comorbid Binge‐Eating Disorder in Female Patients With Generalized Anxiety Disorder, Major Depressive Disorder, and Panic Disorder: A Transdiagnostic Approach
Objective: Many patients with generalized anxiety disorder (GAD), major depressive disorder (MDD), and panic disorder (PD) experience underreported co‐occurring eating pathologies, ranging from subclinical disturbed eating behaviors to full‐threshold Binge‐eating disorder (BED). This study compares the eating attitudes and behaviors of female psychiatric outpatients diagnosed with GAD, PD, and MDD with those of healthy controls while investigating the sociodemographic and clinical factors associated with comorbid BED. Method: The study included a total of 158 female patients diagnosed according to the SCID ‐5, comprising 62 with MDD , 60 with GAD , and 36 with PD , alongside a healthy control group of 168 females. The comorbidity of BED was also evaluated using the SCID ‐5. All participants were administered a sociodemographic data form, the Eating Attitudes Test‐40 ( EAT ‐40), the Beck Depression Inventory ( BDI ), and the Beck Anxiety Inventory ( BAI ). Group differences were assessed through one‐way ANOVA with Bonferroni post hoc adjustments, and independent‐samples t‐tests. Bivariate associations were analyzed using Pearson correlations. Results: The prevalence of disturbed eating attitudes was 31.7% in GAD , 25.0% in PD , 19.3% in MDD , and 5.9% in healthy controls. Compared to controls, EAT ‐40 scores were significantly elevated across all clinical groups ( p < 0.001). In the GAD cohort, current comorbid BED (13.3%) was significantly associated with a younger age ( p = 0.003) and higher BDI ( p = 0.022) and BAI ( p = 0.050) scores. Discussion: This study demonstrated clinically significant eating pathologies and comorbid BED across GAD , PD , and MDD cohorts. These findings empirically support that BED and disordered eating attitudes are associated with worse clinical trajectories across diagnostic groups. Conceptualizing eating disturbances through a transdiagnostic lens may facilitate more comprehensive psychiatric interventions tailored to these patient populations.
- 25 October 2026
- Published by Wiley in International Journal of Eating Disorders
Disordered Eating Behaviors and Comorbid Binge‐Eating Disorder in Female Patients With Generalized Anxiety Disorder, Major Depressive Disorder, and Panic Disorder: A Transdiagnostic Approach
Objective: Many patients with generalized anxiety disorder (GAD), major depressive disorder (MDD), and panic disorder (PD) experience underreported co‐occurring eating pathologies, ranging from subclinical disturbed eating behaviors to full‐threshold Binge‐eating disorder (BED). This study compares the eating attitudes and behaviors of female psychiatric outpatients diagnosed with GAD, PD, and MDD with those of healthy controls while investigating the sociodemographic and clinical factors associated with comorbid BED. Method: The study included a total of 158 female patients diagnosed according to the SCID ‐5, comprising 62 with MDD , 60 with GAD , and 36 with PD , alongside a healthy control group of 168 females. The comorbidity of BED was also evaluated using the SCID ‐5. All participants were administered a sociodemographic data form, the Eating Attitudes Test‐40 ( EAT ‐40), the Beck Depression Inventory ( BDI ), and the Beck Anxiety Inventory ( BAI ). Group differences were assessed through one‐way ANOVA with Bonferroni post hoc adjustments, and independent‐samples t‐tests. Bivariate associations were analyzed using Pearson correlations. Results: The prevalence of disturbed eating attitudes was 31.7% in GAD , 25.0% in PD , 19.3% in MDD , and 5.9% in healthy controls. Compared to controls, EAT ‐40 scores were significantly elevated across all clinical groups ( p < 0.001). In the GAD cohort, current comorbid BED (13.3%) was significantly associated with a younger age ( p = 0.003) and higher BDI ( p = 0.022) and BAI ( p = 0.050) scores. Discussion: This study demonstrated clinically significant eating pathologies and comorbid BED across GAD , PD , and MDD cohorts. These findings empirically support that BED and disordered eating attitudes are associated with worse clinical trajectories across diagnostic groups. Conceptualizing eating disturbances through a transdiagnostic lens may facilitate more comprehensive psychiatric interventions tailored to these patient populations.
- 27 June 2026
- Published by MediHealth Academy in Academic Journal of Neuropsychiatry and Neuropsychology
- Vol. 3 (2) , 46-49
Intranasal esketamine use in treatment-resistant depression: mechanism of action, clinical adverse effects, contraindications, safe administration protocol and treatment process
The U.S. Food and Drug Administration (FDA) has increasingly focused on breakthrough molecular mechanisms, rapidly acting medications, and expanded therapeutic indications in the treatment of depression. During this period, psychiatric interventions targeting N-methyl-D-aspartate (NMDA) receptors and intracellular signaling pathways have gained prominence, moving beyond the traditional monoamine (serotonin/norepinephrine) hypothesis. This article reviews the mechanism of action, clinical adverse effects, contraindications, safe administration protocols, and treatment process associated with esketamine, one of these novel therapeutic approaches.
- 27 June 2026
- Published by MediHealth Academy in Academic Journal of Neuropsychiatry and Neuropsychology
- Vol. 3 (2) , 46-49
Intranasal esketamine use in treatment-resistant depression: mechanism of action, clinical adverse effects, contraindications, safe administration protocol and treatment process
The U.S. Food and Drug Administration (FDA) has increasingly focused on breakthrough molecular mechanisms, rapidly acting medications, and expanded therapeutic indications in the treatment of depression. During this period, psychiatric interventions targeting N-methyl-D-aspartate (NMDA) receptors and intracellular signaling pathways have gained prominence, moving beyond the traditional monoamine (serotonin/norepinephrine) hypothesis. This article reviews the mechanism of action, clinical adverse effects, contraindications, safe administration protocols, and treatment process associated with esketamine, one of these novel therapeutic approaches.